Disc Medicine completes EPP trial enrollment; bitopertin shows PPIX reduction and light tolerance gains

Disc Medicine, Inc.

Enrollment complete for Phase 2 BEACON (n=22 adults) and AURORA (n=75 adults) bitopertin trials in EPP; BEACON expanded to adolescents.
Interim BEACON data: mean PPIX reduction of 39% by Day 43; patients with >30% PPIX reduction averaged >10 hours weekly sunlight tolerance improvement.
Proportion of prodrome-free sunlight challenges rose from 2% to 49%; phototoxic reactions decreased 93% on bitopertin.
Initial DISC-0974 data in MF with anemia shows dose-dependent hepcidin reductions and serum iron increases; no serious AEs reported.
Updated BEACON data and preliminary DISC-0974 results to be presented at ASH Dec 11; conference call same day at 9:30 PM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.